Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer
Purpose Breast cancer (BC) is the most common malignancy among women and prognosis is strongly influenced by tumor subtype. Neoadjuvant chemotherapy (NAC) is the standard treatment for both locally advanced- and early-stage triple-negative and Her2-positive BC. Pathologic complete response (pCR) to...
Gespeichert in:
| Veröffentlicht in: | Archives of gynecology and obstetrics 2023-04, Vol.307 (4), p.1105-1113 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1113 |
|---|---|
| container_issue | 4 |
| container_start_page | 1105 |
| container_title | Archives of gynecology and obstetrics |
| container_volume | 307 |
| creator | von Au, Alexandra Shencoru, Samra Uhlmann, Lorenz Mayer, Luisa Michel, Laura Wallwiener, Markus Hennigs, André Deutsch, Thomas Riedel, Fabian Heil, Joerg Golatta, Michael Schneeweiss, Andreas Schütz, Florian Domschke, Christoph |
| description | Purpose
Breast cancer (BC) is the most common malignancy among women and prognosis is strongly influenced by tumor subtype. Neoadjuvant chemotherapy (NAC) is the standard treatment for both locally advanced- and early-stage triple-negative and Her2-positive BC. Pathologic complete response (pCR) to NAC is an important predictor of patient outcomes. Neutrophil-to-lymphocyte-ratio (NLR) in peripheral blood is associated with prognosis in various malignancies. Here, we investigated the value of the pretreatment NLR as a response predictor in neoadjuvant-treated patients with BC.
Methods
A retrospective chart analysis of 862 patients with invasive BC treated with NAC at the Heidelberg University Hospital during 2003–2015 was conducted. NLR was calculated as the ratio of the absolute neutrophil and lymphocyte counts in peripheral blood, and pCR was defined as absence of invasive or in situ carcinoma in breast and axillary lymph nodes.
Results
A total of 151 patients with invasive BC who underwent NAC were included in this study. NLR tended to be higher in the pCR group than the non-pCR group (
p
|
| doi_str_mv | 10.1007/s00404-022-06726-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10023763</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2787752710</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-a1938da517943f33d69e1f607c38a93a08cdad5cedf74ad69940422815358a233</originalsourceid><addsrcrecordid>eNp9kUtP3DAUha0KVB7tH2CBIrFh49aPJHZWqEKUVkIqC1hbF_uG8SgTB9sZNP--ng6ltIuu_Difz73Hl5ATzj5xxtTnxFjNasqEoKxVoqXqHTnktSxHxfnem_0BOUppyRgXWrfvyYFsOs3qRh8SvI3ovM1-jdUahhmr0FcjzjmGaeEHmgMdNqtpEewmI42Qfaj8WIgAbjmvYcw0R4SMrpqKiGNO1bPPi-qh3KZcWRgtxg9kv4ch4ceX9Zjcf726u_xGb35cf7_8ckNtrZpMgXdSO2i46mrZS-naDnnfMmWlhk4C09aBayy6XtVQ1K7kF0LzRjYahJTH5GLnO80PK3S2tBNhMFP0K4gbE8Cbv5XRL8xjWJvyn0Kqdutw_uIQw9OMKZuVTxaHAUrkORmhmOy0rJkq6Nk_6DLMcSz5CqWVaoTirFBiR9kYUorYv3bD2basMrsxmjJG82uMZmt9-jbH65PfcyuA3AGpSOMjxj-1_2P7E_r3qgw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2787752710</pqid></control><display><type>article</type><title>Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>von Au, Alexandra ; Shencoru, Samra ; Uhlmann, Lorenz ; Mayer, Luisa ; Michel, Laura ; Wallwiener, Markus ; Hennigs, André ; Deutsch, Thomas ; Riedel, Fabian ; Heil, Joerg ; Golatta, Michael ; Schneeweiss, Andreas ; Schütz, Florian ; Domschke, Christoph</creator><creatorcontrib>von Au, Alexandra ; Shencoru, Samra ; Uhlmann, Lorenz ; Mayer, Luisa ; Michel, Laura ; Wallwiener, Markus ; Hennigs, André ; Deutsch, Thomas ; Riedel, Fabian ; Heil, Joerg ; Golatta, Michael ; Schneeweiss, Andreas ; Schütz, Florian ; Domschke, Christoph</creatorcontrib><description>Purpose
Breast cancer (BC) is the most common malignancy among women and prognosis is strongly influenced by tumor subtype. Neoadjuvant chemotherapy (NAC) is the standard treatment for both locally advanced- and early-stage triple-negative and Her2-positive BC. Pathologic complete response (pCR) to NAC is an important predictor of patient outcomes. Neutrophil-to-lymphocyte-ratio (NLR) in peripheral blood is associated with prognosis in various malignancies. Here, we investigated the value of the pretreatment NLR as a response predictor in neoadjuvant-treated patients with BC.
Methods
A retrospective chart analysis of 862 patients with invasive BC treated with NAC at the Heidelberg University Hospital during 2003–2015 was conducted. NLR was calculated as the ratio of the absolute neutrophil and lymphocyte counts in peripheral blood, and pCR was defined as absence of invasive or in situ carcinoma in breast and axillary lymph nodes.
Results
A total of 151 patients with invasive BC who underwent NAC were included in this study. NLR tended to be higher in the pCR group than the non-pCR group (
p
< 0.1). Analyses of BC subtypes demonstrated that NLR was significantly higher in the pCR- compared with the non-pCR group (3.304 vs. 2.379, respectively;
p
= 0.048) in patients with luminal B/Her2-negative tumors. Further, we found a significant difference in NLR according to remission status in postmenopausal patients (2.861 vs. 2.313, respectively;
p
= 0.043).
Conclusion
NLR was significantly higher only for patients achieving pCR in the Luminal B/Her2-negative and postmenopausal subgroups. Hence, NLR is a candidate additional predictive factor in patients with Luminal B/Her2-negative BC.</description><identifier>ISSN: 1432-0711</identifier><identifier>ISSN: 0932-0067</identifier><identifier>EISSN: 1432-0711</identifier><identifier>DOI: 10.1007/s00404-022-06726-7</identifier><identifier>PMID: 35980458</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Endocrinology ; Female ; Gynecologic Oncology ; Gynecology ; Human Genetics ; Humans ; Lymphocytes ; Lymphocytes - pathology ; Medicine ; Medicine & Public Health ; Neoadjuvant Therapy ; Neutrophils ; Neutrophils - pathology ; Obstetrics/Perinatology/Midwifery ; Prognosis ; Receptor, ErbB-2 ; Retrospective Studies</subject><ispartof>Archives of gynecology and obstetrics, 2023-04, Vol.307 (4), p.1105-1113</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-a1938da517943f33d69e1f607c38a93a08cdad5cedf74ad69940422815358a233</citedby><cites>FETCH-LOGICAL-c475t-a1938da517943f33d69e1f607c38a93a08cdad5cedf74ad69940422815358a233</cites><orcidid>0000-0001-7649-4914</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00404-022-06726-7$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00404-022-06726-7$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35980458$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>von Au, Alexandra</creatorcontrib><creatorcontrib>Shencoru, Samra</creatorcontrib><creatorcontrib>Uhlmann, Lorenz</creatorcontrib><creatorcontrib>Mayer, Luisa</creatorcontrib><creatorcontrib>Michel, Laura</creatorcontrib><creatorcontrib>Wallwiener, Markus</creatorcontrib><creatorcontrib>Hennigs, André</creatorcontrib><creatorcontrib>Deutsch, Thomas</creatorcontrib><creatorcontrib>Riedel, Fabian</creatorcontrib><creatorcontrib>Heil, Joerg</creatorcontrib><creatorcontrib>Golatta, Michael</creatorcontrib><creatorcontrib>Schneeweiss, Andreas</creatorcontrib><creatorcontrib>Schütz, Florian</creatorcontrib><creatorcontrib>Domschke, Christoph</creatorcontrib><title>Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer</title><title>Archives of gynecology and obstetrics</title><addtitle>Arch Gynecol Obstet</addtitle><addtitle>Arch Gynecol Obstet</addtitle><description>Purpose
Breast cancer (BC) is the most common malignancy among women and prognosis is strongly influenced by tumor subtype. Neoadjuvant chemotherapy (NAC) is the standard treatment for both locally advanced- and early-stage triple-negative and Her2-positive BC. Pathologic complete response (pCR) to NAC is an important predictor of patient outcomes. Neutrophil-to-lymphocyte-ratio (NLR) in peripheral blood is associated with prognosis in various malignancies. Here, we investigated the value of the pretreatment NLR as a response predictor in neoadjuvant-treated patients with BC.
Methods
A retrospective chart analysis of 862 patients with invasive BC treated with NAC at the Heidelberg University Hospital during 2003–2015 was conducted. NLR was calculated as the ratio of the absolute neutrophil and lymphocyte counts in peripheral blood, and pCR was defined as absence of invasive or in situ carcinoma in breast and axillary lymph nodes.
Results
A total of 151 patients with invasive BC who underwent NAC were included in this study. NLR tended to be higher in the pCR group than the non-pCR group (
p
< 0.1). Analyses of BC subtypes demonstrated that NLR was significantly higher in the pCR- compared with the non-pCR group (3.304 vs. 2.379, respectively;
p
= 0.048) in patients with luminal B/Her2-negative tumors. Further, we found a significant difference in NLR according to remission status in postmenopausal patients (2.861 vs. 2.313, respectively;
p
= 0.043).
Conclusion
NLR was significantly higher only for patients achieving pCR in the Luminal B/Her2-negative and postmenopausal subgroups. Hence, NLR is a candidate additional predictive factor in patients with Luminal B/Her2-negative BC.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Gynecologic Oncology</subject><subject>Gynecology</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Lymphocytes</subject><subject>Lymphocytes - pathology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoadjuvant Therapy</subject><subject>Neutrophils</subject><subject>Neutrophils - pathology</subject><subject>Obstetrics/Perinatology/Midwifery</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2</subject><subject>Retrospective Studies</subject><issn>1432-0711</issn><issn>0932-0067</issn><issn>1432-0711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kUtP3DAUha0KVB7tH2CBIrFh49aPJHZWqEKUVkIqC1hbF_uG8SgTB9sZNP--ng6ltIuu_Difz73Hl5ATzj5xxtTnxFjNasqEoKxVoqXqHTnktSxHxfnem_0BOUppyRgXWrfvyYFsOs3qRh8SvI3ovM1-jdUahhmr0FcjzjmGaeEHmgMdNqtpEewmI42Qfaj8WIgAbjmvYcw0R4SMrpqKiGNO1bPPi-qh3KZcWRgtxg9kv4ch4ceX9Zjcf726u_xGb35cf7_8ckNtrZpMgXdSO2i46mrZS-naDnnfMmWlhk4C09aBayy6XtVQ1K7kF0LzRjYahJTH5GLnO80PK3S2tBNhMFP0K4gbE8Cbv5XRL8xjWJvyn0Kqdutw_uIQw9OMKZuVTxaHAUrkORmhmOy0rJkq6Nk_6DLMcSz5CqWVaoTirFBiR9kYUorYv3bD2basMrsxmjJG82uMZmt9-jbH65PfcyuA3AGpSOMjxj-1_2P7E_r3qgw</recordid><startdate>20230401</startdate><enddate>20230401</enddate><creator>von Au, Alexandra</creator><creator>Shencoru, Samra</creator><creator>Uhlmann, Lorenz</creator><creator>Mayer, Luisa</creator><creator>Michel, Laura</creator><creator>Wallwiener, Markus</creator><creator>Hennigs, André</creator><creator>Deutsch, Thomas</creator><creator>Riedel, Fabian</creator><creator>Heil, Joerg</creator><creator>Golatta, Michael</creator><creator>Schneeweiss, Andreas</creator><creator>Schütz, Florian</creator><creator>Domschke, Christoph</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7649-4914</orcidid></search><sort><creationdate>20230401</creationdate><title>Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer</title><author>von Au, Alexandra ; Shencoru, Samra ; Uhlmann, Lorenz ; Mayer, Luisa ; Michel, Laura ; Wallwiener, Markus ; Hennigs, André ; Deutsch, Thomas ; Riedel, Fabian ; Heil, Joerg ; Golatta, Michael ; Schneeweiss, Andreas ; Schütz, Florian ; Domschke, Christoph</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-a1938da517943f33d69e1f607c38a93a08cdad5cedf74ad69940422815358a233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Gynecologic Oncology</topic><topic>Gynecology</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Lymphocytes</topic><topic>Lymphocytes - pathology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoadjuvant Therapy</topic><topic>Neutrophils</topic><topic>Neutrophils - pathology</topic><topic>Obstetrics/Perinatology/Midwifery</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>von Au, Alexandra</creatorcontrib><creatorcontrib>Shencoru, Samra</creatorcontrib><creatorcontrib>Uhlmann, Lorenz</creatorcontrib><creatorcontrib>Mayer, Luisa</creatorcontrib><creatorcontrib>Michel, Laura</creatorcontrib><creatorcontrib>Wallwiener, Markus</creatorcontrib><creatorcontrib>Hennigs, André</creatorcontrib><creatorcontrib>Deutsch, Thomas</creatorcontrib><creatorcontrib>Riedel, Fabian</creatorcontrib><creatorcontrib>Heil, Joerg</creatorcontrib><creatorcontrib>Golatta, Michael</creatorcontrib><creatorcontrib>Schneeweiss, Andreas</creatorcontrib><creatorcontrib>Schütz, Florian</creatorcontrib><creatorcontrib>Domschke, Christoph</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Archives of gynecology and obstetrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>von Au, Alexandra</au><au>Shencoru, Samra</au><au>Uhlmann, Lorenz</au><au>Mayer, Luisa</au><au>Michel, Laura</au><au>Wallwiener, Markus</au><au>Hennigs, André</au><au>Deutsch, Thomas</au><au>Riedel, Fabian</au><au>Heil, Joerg</au><au>Golatta, Michael</au><au>Schneeweiss, Andreas</au><au>Schütz, Florian</au><au>Domschke, Christoph</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer</atitle><jtitle>Archives of gynecology and obstetrics</jtitle><stitle>Arch Gynecol Obstet</stitle><addtitle>Arch Gynecol Obstet</addtitle><date>2023-04-01</date><risdate>2023</risdate><volume>307</volume><issue>4</issue><spage>1105</spage><epage>1113</epage><pages>1105-1113</pages><issn>1432-0711</issn><issn>0932-0067</issn><eissn>1432-0711</eissn><abstract>Purpose
Breast cancer (BC) is the most common malignancy among women and prognosis is strongly influenced by tumor subtype. Neoadjuvant chemotherapy (NAC) is the standard treatment for both locally advanced- and early-stage triple-negative and Her2-positive BC. Pathologic complete response (pCR) to NAC is an important predictor of patient outcomes. Neutrophil-to-lymphocyte-ratio (NLR) in peripheral blood is associated with prognosis in various malignancies. Here, we investigated the value of the pretreatment NLR as a response predictor in neoadjuvant-treated patients with BC.
Methods
A retrospective chart analysis of 862 patients with invasive BC treated with NAC at the Heidelberg University Hospital during 2003–2015 was conducted. NLR was calculated as the ratio of the absolute neutrophil and lymphocyte counts in peripheral blood, and pCR was defined as absence of invasive or in situ carcinoma in breast and axillary lymph nodes.
Results
A total of 151 patients with invasive BC who underwent NAC were included in this study. NLR tended to be higher in the pCR group than the non-pCR group (
p
< 0.1). Analyses of BC subtypes demonstrated that NLR was significantly higher in the pCR- compared with the non-pCR group (3.304 vs. 2.379, respectively;
p
= 0.048) in patients with luminal B/Her2-negative tumors. Further, we found a significant difference in NLR according to remission status in postmenopausal patients (2.861 vs. 2.313, respectively;
p
= 0.043).
Conclusion
NLR was significantly higher only for patients achieving pCR in the Luminal B/Her2-negative and postmenopausal subgroups. Hence, NLR is a candidate additional predictive factor in patients with Luminal B/Her2-negative BC.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>35980458</pmid><doi>10.1007/s00404-022-06726-7</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7649-4914</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1432-0711 |
| ispartof | Archives of gynecology and obstetrics, 2023-04, Vol.307 (4), p.1105-1113 |
| issn | 1432-0711 0932-0067 1432-0711 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10023763 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Endocrinology Female Gynecologic Oncology Gynecology Human Genetics Humans Lymphocytes Lymphocytes - pathology Medicine Medicine & Public Health Neoadjuvant Therapy Neutrophils Neutrophils - pathology Obstetrics/Perinatology/Midwifery Prognosis Receptor, ErbB-2 Retrospective Studies |
| title | Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T07%3A58%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictive%20value%20of%20neutrophil-to-lymphocyte-ratio%20in%20neoadjuvant-treated%20patients%20with%20breast%20cancer&rft.jtitle=Archives%20of%20gynecology%20and%20obstetrics&rft.au=von%20Au,%20Alexandra&rft.date=2023-04-01&rft.volume=307&rft.issue=4&rft.spage=1105&rft.epage=1113&rft.pages=1105-1113&rft.issn=1432-0711&rft.eissn=1432-0711&rft_id=info:doi/10.1007/s00404-022-06726-7&rft_dat=%3Cproquest_pubme%3E2787752710%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2787752710&rft_id=info:pmid/35980458&rfr_iscdi=true |